Dendrimer-based polypeptide nano vaccine as well as preparation method and application thereof

By preparing peptide nanovaccines loaded with MnO2 nanoparticles, and combining chemical kinetics and immunotherapy, the toxicity of traditional cancer treatments and the limitations of immunotherapy have been overcome, achieving highly efficient tumor killing and immune response, and showing potential for clinical application.

CN121818907APending Publication Date: 2026-04-10DONGHUA UNIV
0 Cites 0 Cited by

Patent Information

Application Number
CN202511764070.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-11-27
Publication Date
2026-04-10

AI Technical Summary

Technical Problem

Traditional cancer treatments suffer from systemic toxicity, drug resistance, and the inability to completely eliminate cancer cells. Low tumor immunogenicity, insufficient T-cell infiltration, and low antigen presentation efficiency limit the clinical application of tumor immunotherapy.

Method used

By loading MnO2 nanoparticles with functionalized dendritic macromolecules and encapsulating peptide antigens, peptide nanovaccines were prepared to achieve chemokinetics/immunotherapy. MnO2 consumes glutathione in the tumor microenvironment to generate Mn2+, which catalyzes the decomposition of H2O2 into toxic hydroxyl radicals to kill tumors through a Fenton-like reaction, and activates the cGAS-STING pathway to trigger a strong immune response.

Benefits of technology

It achieves chemokinetic therapy and immune activation of tumors, effectively inhibiting tumor growth and recurrence, and has potential clinical application value.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention relates to a dendrimer-based polypeptide nano vaccine as well as a preparation method and application thereof. The polypeptide nano vaccine is obtained by loading MnO2 nano particles on a functionalized dendrimer and wrapping a polypeptide antigen. After the polypeptide nano vaccine disclosed by the invention is injected into a mouse body through peritumoral injection, MnO2 plays a chemical kinetic treatment role through a Fenton-like reaction, and tumor cells are induced to generate immunogenic cell death, so that dendritic cell maturation is promoted; meanwhile, the polypeptide nano vaccine can activate an immune system and initiate potent immune response by activating a cGAS-STING pathway and being cooperated and combined with presentation of a polypeptide antigen OVA257-264, a new chemical kinetics / immune combined treatment strategy is provided, and the polypeptide nano vaccine has a remarkable inhibition effect on tumor growth and recurrence and has potential application value in the field of biological medicine.
Need to check novelty before this filing date? Find Prior Art